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Abstract
Ductal adenocarcinoma of the pancreas is ranking 4 for patient’ death from malignant disease in Western countries, with no
satisfactory treatment. We re-examined more precisely the histone deacetylases (HDAC) and Sirtuin (SIRT) gene expression
patterns in pancreatic cancer with more pancreatic tumors and normal tissues. We also examinedthe possible relationship
between HDAC gene expression levels and long term disease outcome. Moreover, we have evaluated by using an in vitro
model system of human pancreatic tumor cell line whether HDAC7 knockdown may affect the cell behavior. We analyzed 29
pancreatic adenocarcinoma (PA), 9 chronic pancreatitis (CP), 8 benign pancreatic (BP) and 11 normal pancreatic tissues.
Concerning pancreatic adenocarcinoma, we were able to collect biopsies at the tumor periphery. To assess the possible
involvement of HDAC7 in cell proliferation capacity, we have generated recombinant human Panc-1 tumor which
underexpressed or overexpressed HDAC7. The expression of HDAC1,2,3,4,7 and Nur77 increased in PA samples at levels
significantly higher than those observed in the CP group (p= 0.0160; 0.0114; 0.0227; 0.0440; 0.0136; 0.0004, respectively).
The expression of HDAC7, was significantly greater in the PA compared with BP tissue samples (p= 0.05). Mean mRNA
transcription levels of PA for HDAC7 and HDAC2 were higher when compared to their counterpart biopsies taken at the
tumor periphery (p= 0.0346, 0.0053, respectively). Moreover, the data obtained using confocal microscopy and a
quantitative method of immunofluorescence staining strongly support the HDAC7 overexpression in PA surgical specimens.
The number of deaths and recurrences at the end of follow up were significantly greater in patients with overexpression of
HDAC7. Interestingly, the rate of growth was significantly reduced in the case of cell carrying shRNA construct targeting
HDAC7 encoding gene when compared to the parental Panc-1 tumor cells (p = 0.0015) at 48 h and 96 h (p = 0.0021). This
study strongly support the notion that HDAC7play a role in pancreatic adenocarcinoma progression.
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Introduction
Ductal adenocarcinoma of the pancreas is ranking 4 for patient’
death from malignant disease in Western countries [1]. The
aggressiveness of this cancer is demonstrated by a disease-related
mortality rate closely approximating the incidence [2]. Cancer
diffusion and metastasis account for approximately 90% of all
cancer related deaths [2]. Metastasis follows a multi-step complex
processes in which neighboring healthy tissue is invaded by
primary tumor cells, which access the systemic circulation and
finally proliferate at distant sites into macroscopic secondary
tumors via the perivascular and/or perilymphatic tissue [3]. In the
case of pancreatic cancer, most of the patients already have
metastases at the time of diagnosis. A number of investigations
have focused on the identification of possible markers that may
allow for early diagnosis of pancreatic cancer. Specific events that
promote tumorigenesis and cancer progression are linked with
complex molecular modifications such as DNA methylation,
histone acetylation, phosphorylation, ubiquitylation and ADP
ribosylation. Currently, results from basic research underline the
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e108520
importance of acetylation and deacetylation at the level of not only
histone lysine residues but also other cellular factors that are
supposed to interfere with the regulation of gene expression. In
fact, the steady-sate of acetylation of core histones is controlled by
the opposing actions histone actetyltransferases (HATs) and
histone deacetylases (HDACs) whose activities are correlated with
gene activation and gene repression or silencing [4]. Growing
knowledge about HDACs shows that they are regulators of
growth, differentiation and cell death (apoptosis). The dysfunction
of transcriptional repression mediated by HDACs may lead to
carcinogenesis. Indeed, modulation of expression levels of genes
encoding HDACs (over- and/or under-expression) has been
reported for different types of cancer [5,6,7,8]. The characteriza-
tion of key genes that play a role in pancreatic tumor development
may not only allow to uncover new biomarkers, which will become
the focus of intensive research interest, but will also shed light on
potential gene products to be exploited for the design of selective
means to interfere with tumor progression. Recent studies
demonstrated [9,10] that HDAC2 was overexpressed in pancre-
atic adenocarcinoma tissue samples. In order to provide insight
into the biological behavior of pancreatic cancer and identify new
potential biomarkers, we have in the past few years initiated a
study aiming to examine the levels of HDAC and SIRT genes
expression in a set of surgically resected pancreatic tissues
including 11 pancreatic adenocarcinoma samples and a normal
pancreas tissue. Despite relatively small number of specimens
examined, we found increased expression of HDAC7, a class IIa
deacetylase, in 9 out of 11 samples [11,12]. However, although we
have used one normal pancreatic as the calibrator for gene
expression measurement and other samples in close proximity or
far away from the tumor as controls, we thought that further
investigations using a greater number of normal pancreatic tissues
and tumor samples are needed to re-examine more precisely the
HDAC and SIRTs gene expression patterns in pancreatic cancer.
Moreover, attempts were made to examine the possible relation-
ship between HDAC gene expression and the disease outcome.
We also evaluate by using an in vitro model system of human
pancreatic tumor cell line whether HDAC7 knockdown may affect
the cell behavior.
Materials and Methods
Subject population
From May 2007 through August 2012, 29 pancreatic adeno-
carcinoma (PA), 9 chronic pancreatitis (CP), 8 benign pancreatic
tumors including serous cystadenoma (SC) n= 2, mucinous
cystadenoma (n = 2), benign IMPN (n= 2), benign cyst (retentional
cyst, n = 1), and pancreatic endocrine tumor (n= 1), were taken in
charge in the department of Surgery at la Timone Hospital
(Marseille, France). All patients underwent contrast-enhanced
thoracic and abdominal computed tomography, abdominal
ultrasonography, magnetic resonance imaging and blood testing.
PA had no preoperative treatment before surgery. Twenty two
pancreaticoduodenectomies (PD), and 7 left pancreatectomies
were conducted for pancreatic adenocarcinoma, respectively. Two
PD, 4SP and 3 Frey procedures [13]were performed for CP. Four
PD, 2 SP and 2 medial pancreatectomies were performed for
benign lesions. Four normal pancreatic (NP) biopsies were
obtained during liver transplantation on the donor hepatectomy,
7others were obtained during susmesocolic surgery when radical
gastrectomy required left pancreatectomy: 3 ampulloma (AP1-3), 2
cholangiocarcinoma of the principal bile duct (BD1-2), 1
gastrinoma of the duodenum (G), 1 normal adjacent tissues
samples after gastric resection for gastric adenocarcinoma. In
addition, 11 samples of control tissues taken at the periphery of the
surgical specimens from different patients with PA were also
included in this study. Data were prospectively collected and a
standardized questionnaire was completed at the time of follow up
and of study assessment. Prior to surgery all patients had signed an
informed consent form that had been approved by the local ethics
committee. Protection committee people of South Mediterranean
II, approved by Ministerial Order dated May 31, 2012,
constituted under the order of the Director General of Health
Agency Region Provence Alpes Coˆte d’Azur dated 13 June 2012,
composed of: L. BOYER, V. PRADEL, B. DUSSOL, C.
SICHEL, M. CAILLOL, F. VINCENT, G. NAURAYE, JP.
VIDAL, O. SCHWEITZER, J. ACCIARO, discussed in plenary
the declaration file storage and preparation for scientific elements
of the human body identified by the Ministry of Higher Education
and Research under the reference DC-2013-1857 and whose
scientific director is Mr Dominique LOMBARDO, gave a
favorable expert advice (Files S1, S2).
Surgery
All surgical procedures were performed by three experienced
pancreatic surgeons (BS, YPLT, IS, MO). Experienced senior
surgeons carried out all pancreatic head resections. PD was
performed using a pylorus preserving or Whipple procedure, and
an end-to-end pancreaticojejunostomy (PJA) was constructed with
a single-layer anastomosis of interrupted 5–0 PDS (Ethicon
surgery) absorbable sutures. Choice of surgical technique was
decided per-operatively bound to surgeon’s decision. Anterior
SMA approach was then routinely used since the year 2001 to
standardize the radicality of resection at the site of the
retroperitoneal margin. Standard lymphadenectomy was per-
formed before the year 2001 and extended lymphadenectomy
since that time [14]. Frozen section examinations at the pancreatic
trans-section line, was performed in all cases and was not invaded
for all PA. Standard lymphadenectomy was carried out along the
hepatoduodenal ligament and the common hepatic artery [15]. All
resections were performed via laparotomy. In the case of left
pancreatectomy: the technique of distal pancreatectomy beginning
with division of pancreatic neck before control of splenic vessels
was used [16]. Early neck division allows safer vascular control.
For distal pancreatectomy, primary section of the neck and splenic
vessels ligation, combined with division of left gastro-epiploic and
short gastric vessels, precedes mobilization of a devascularized
specimen, decreases operative bleeding and seems most suited
from a carcinologic point of view. After surgery patients received
adjuvant chemotherapy in function of their performance status,
and at the discretion of the oncologist. Two soft drains (Peters) or
left pancreatic section for the left pancreatectomy were routinely
placed near the pancreaticojejunal anastomose. Operative time
was recorded. In the absence of a fistula, drains were removed
after 7 days.
Tissue samples
All surgical specimens were reviewed by a senior pathologist.
Clinical and pathologic staging (Table S1) were reassessed
according to American Joint Committee on Cancer TNM staging
of pancreatic cancer concerning PA. The tumors had been snap-
frozen in RNA later and liquid nitrogen during 15 seconds and
immediately stored at 280uC. Tumors characteristics were
recorded in all patients (Table S1). This included its location,
median size at diagnosis, UICC staging, extension of the
neoplastic disease at diagnosis, number of metastasis sites when
present and the nodal status. All specimens were graded according
to the classification rules of the 6th edition (2002) of the American
HDAC and SIRT Gene Expression and Pancreatic Cancer
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Joint Committee on Cancer Staging Manuel (AJCC) [17]. The
radicality of resection was graded according to R-classification of
the International Union against Cancer (R0: no residual tumor,
R1: microscopic residual tumor, R2: macroscopic residual tumor
in situ) [18]. The retroperitoneal margin was graded R1 if residual
microscopic tumor was identified within 1 mm of the trans-section
line [19]. Since the year 2002, the pathological examination of the
surgical specimen was standardized according to the Luttges et al.
protocol [20], by using routine ink marking of the retroperitoneal
trans-section line. In cases of vascular resection, the complete
vascular segment was embedded and both ends were examined
separately as additional resection margins.
Tissue Treatment and immunofluorescence histological
Study
Tissue specimens (21 PA and 6 NP samples) were routinely fixed
in 10% formalin, embedded in paraffin and further cut into 5 mm
sections immediately stored at 4uC or stained with hematoxylin-
phloxine-saffron (HPS).
Reagents and mAbs
In the case of Western blot analysis, a mouse monoclonal anti-
actin antibody and POD-labelled anti-mouse antibody {from
Sigma (St Louis, MO)}, were used. A rabbit polyclonal anti-
HDAC7 antibody was from Euromedex (Souffelweyersheim,
France), POD-labelled anti-rabbit antibody was from Cell
Signaling (Beverly, MA). DMEM cell culture media, penicillin,
streptomycin, trypsin-EDTA, hygromycin B and neomycin were
from InVitrogen(Carlsbad, NM)To conduct the immunostaining,
mouse monoclonal antibody (mAb) anti-HDAC7 (20 mg/mL,
Sigma-Aldrich, France), and a rabbit anti-Nur77 antibody (Ab)
(5 mg/mL, Thermo Scientific, CergyPontoise, France) were used.
Biotin-conjugated F(ab’)2 fragment of goat antibodies to mouse
IgG (Beckman Coulter, Roissy CDG, France) or biotin-conjugated
goat anti-rabbit IgG (Sigma-Aldrich) for HDAC7 and Nur77
immunostaining respectively were used.
Immunofluorescence
Formalin-fixed, paraffin-embedded tissue sections (5 mm) were
deparaffinized and treated with an antigen retrieval solution.
Tissue sections were incubated 2 h at room temperature (RT) with
anti-HDAC7 or anti-Nur77 and washed in PBS. Sections were
then washed in PBS and incubated 1 h at RT with 1:50 dilution of
biotin-conjugated F(ab’)2 fragment of goat antibodies to mouse
IgG or biotin-conjugated goat anti-rabbit IgG for HDAC7 and
Nur77 immunostaining respectively. The sections were washed in
PBS, treated 1 h at RT with 1:50 dilution of streptavidin-
fluorescein (Beckman Coulter). All sections were mounted in Dako
aqueous permanent mounting medium.
Sections were observed by means of a Zeiss Axiovert 200 M
inverted microscope with 20 objective and a confocal laser
scanning microscope (CLSM) (Leica, TCS SP5) with a 60
objective. An argon laser with an excitation of 488 nm was used
to activate the green fluorescence.
Image Processing
Images were processed as previously described [11]. For each
primary antibody, the staining was calculated as the ratio between
the total fluorescence of the area (total specific fluorescence) and
the surface of this area (mean specific fluorescence, MSF). Mean
values of six stained areas for each biopsy were then calculated.
Follow up
Postoperative follow-up includes clinical, biochemical, and
radiological assessment every 3 months during the first postoper-
ative year, then, every 6 months up to a postoperative delay of 5
years and afterward every year up to 10 years of follow-up. None
patient was lost of follow up. The surviving patients were assessed
for disease recurrence and site of recurrence. Follow-up informa-
tion was obtained from medical records and direct patients’
consultation. Follow up was continued for all patients in this
cohort to June 2013 without including new patients. Long-term
follow-up was available for all patients. The mean duration of
Figure 1. Quantitative real-time Q RT-PCR. Mean Cp of HDACs, SIRTs and Nurr77 genes and 28S transcripts of tissues samples from the control
group. qPCR were run in triplicates on two independent cDNA preparations from pancreatic tissues as described in Materials and Methods section.
The mean Cp values Ct (mean of Cp) were determined for the following samples: NP-1 to 4, normal pancreas; BD-1 and 2, normal pancreas samples
from patients carrying biliary duct tumors. AP-1 to 3: normal adjacent tissues samples ampulloma; G-A: normal adjacent tissues samples after gastric
resection for gastric adenocarcinoma; Gastrinoma: normal adjacent tissues samples for gastrinoma of the duodenum.
doi:10.1371/journal.pone.0108520.g001
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follow-up was 16 months (median: 18 months, range: 2–53). The
length of survival was calculated from the date of the operation
until the date of death or the date which the present study was
ended.
Cell growth and proliferation
Panc-1 cells (ATCC, CRL-1469) originated from human
pancreatic carcinoma were grown in DMEM medium supple-
mented with 10% FCS, 1% penicillin (100 U/ml), 1% strepto-
mycin (100 mg/ml) and glutamine (1 mM). Cells were seeded at
4000 cells per well in a 96-wells plate and cell growth was assessed
at 24, 48, 72 and 96 h by 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl
(MTT) assay. Results are given as mean 6SD (n= 8) and are
representative of at least 3 independent experiments.
Cells transfection
Silencing of HDAC7 gene was performed by stable transfection
of Panc-1 cells with SureSilencing shRNA Plasmid for Human
HDAC7 (Qiagen, Courtaboeuf, France), which confers hygro-
mycin resistance to transfected cells. Over expression of HDAC7
was performed by stable transfection using pCDNA3-HDAC7-
Flag plasmid (plasmid Addgene 13824; Eric Verdin, The J. David
Gladstone Institutes, San Francisco, CA, [21]), which confers
neomycin resistance to transfected cells. Panc-1 cells at 50-80%
confluence were transfected with Lipofectamine LTX Reagent
with PLUS Reagent (InVitrogen) according to the manufacturer’
instructions. After a 6 h incubation at 37uC in 5% CO2, the
transfection medium was replaced with complete DMEM medium
for 48 h and then with fresh medium containing 300 mg/ml
hygromycin B (shRNA plasmid) or 2 mg/ml neomycin (pCDNA3-
HDAC7-Flag plasmid). After 1–2weeks, in selective medium a
limit dilution was performed. Selected clones were referred to as
SH or pFLAG cell clones, respectively. Control transfections were
carried out using shRNA CTL vector or pCDNA3 empty vector.
SDS-PAGE and Western blotting
Cells were washed three times with ice-cold PBS, harvested and
pelleted by centrifugation. Pellets were washed twice and lysed at
4uC in 0.1 ml of lysis buffer {50 mM Tris/HCl pH 7.5, 100 mM
NaCl, 0.5% Triton X-100, 1 mM EDTA, protease inhibitors
(Complete TM, Roche Diagnostics)}. Homogenates were incu-
bated for 30 min at 4uC and clarified by centrifugation at 10 000 g
for 30 min at 4uC and frozen at 220uC. An aliquot was saved for
protein determination using the Bicinchoninic Acid Kit (Sigma, St
Louis). Equal amounts of cell lysates (100 mg) in reducing SDS
buffer were resolved on gradient 8–16% Tris-Glycine polyacryl-
amide gels (Pierce). After electrophoretic migration, proteins were
transferred onto nitrocellulose membranes and processed for
immunoblotting by using appropriate primary and secondary
antibodies. After washes, membranes were revealed by chemilu-
minescence (Roche diagnostic, Meylan, France).
RNA isolation and reverse transcription
The tissues (<30 mg) were disrupted in 600 ml Buffer RLT Plus
(Qiagen) using an adapted sized vessel for disruption and
homogenization with a Tissue Ruptor. Total RNA was isolated
using the All Prep DNA/RNA mini kit (Qiagen) according to the
manufacturer’s instructions. RNA concentration was determined
by absorption and RNA integrity was checked on RNA Nano
chips (Agilent, Santa Clara, CA). Reverse transcription (RT)
reactions were performed on 1 mg of total RNA using Improm-II
Kit (Promega, Madison, WI) according to the manufacturer’s
instructions. T he cells were harvested and pellets for RNA
purification were processed immediately in RLT lysis buffer
(Qiagen). Total RNA was isolated using the RNeasy mini kit
(Qiagen) according to the manufacturer’s instructions. RNA
samples were treated with DNase I (DNA-free kit, Ambion Inc.,
Austin, Texas) to remove traces of contaminant genomic DNA.
Reverse transcription (RT) reactions were performed on 1 mg of
total RNA using random hexamers and the M-MLV reverse
transcriptase (Invitrogen) according to the manufacturer’s instruc-
tions.
Real-time quantitative PCR (Q RT-PCR)
Q RT-PCR reactions were run in triplicate on two independent
RNA preparations from cellular clones using the LightCycler480
SYBR Green I Master mix and the LightCycler real time PCR
instrument (Roche Molecular Biochemicals, Mannheim, Ger-
many) as described previously [12]. The primers are summarized
in Table S2. Primers were designed to amplify an approximately
200 bp fragment in the coding sequence of 11 genes belonging to
the HDAC/SIR families. The 28S RN gene was chosen as
control. Comparative analysis of Crossing Point Ct values (mean
of Cp) of the 4 NP and the 7 normal pancreatic biopsies for the set
of HDAC and SIRT as well as Nur77 genes revealed that they
were of similar values with no statistically significant difference
(Figure 1, Table S3). Therefore, the 11 biopsies samples were
designed as a control group (CG) and their mean Cp values for all
genes were determined and used as the calibrator. The 22DDCt
method was used to analyze the relative gene expression [22]. The
average Ct (Cp values) was calculated for both the target and the
28S gene and the DCt (C t,target-C t,28S) was determined. The CG
was used as the calibrator [for calculation of DDCt= (C t,target-C t,
28S)-(C t,target CG-C t,28S CG)] [22]. For the CG, DDCt equals zero
and 20 equals one, so that the fold change in gene expression
relative to the CG equals one. Evaluation of 22DDCt indicates the
fold change in gene expression relative to the CG.
Statistical analysis
Statistical analysis was performed using Graph Pad 5 software.
Data are expressed as mean 6 the standard deviation or median
with interquartile range. The differences between two groups were
analyzed using the Mann-Whitney U test or student test t. One-
way analysis of variance or Kruskal-wallis test was performed to
compare more than two groups.
To compare for categorical variables, the chi-square test or
Fisher exact was used. Kaplan-Meier method was used to estimate
overall and relapse-free survival. For all tests, a p-value of less than
0.05 was considered significant.
Results
Expression of HDAC, SIRT and Nurr77 in control
pancreatic tissues
Panel of 11 normal pancreas surgical specimens were studied.
These tissues samples were evaluated for HDACs, SIRTs and
Nur77 mRNA status by quantitative real-time PCR. As shown in
Figure 2. Expression of HDACs, SIRTs and Nurr77 in pancreatic adenocarcinoma (PA) and control group (CG) by Q RT-PCR. Samples
were run in triplicate on two independent cDNA preparations from pancreatic tissues as described in Materials and Methods section. (Cp) Crossing
point values. Comparisons were made by Wilcoxon test and differences were considered significant at p,0.05.
doi:10.1371/journal.pone.0108520.g002
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Figure 1 and Table S3) when considering the crossing point (Cp)
which defines the point at which the fluorescence rises appreciably
above the back ground fluorescence, the values observed for each
gene were not statistically significantly different (the p values
varied from 0.13 to 1) suggesting that the target genes were
expressed at similar levels in the surgical specimens examined.
This allowed us to define the 11 surgical specimens as a control
group (CG), therefore using the mean values of their Cps as the
calibrator.
Comparison of Q RT-PCR analysis of HDACs, SIRTs and
Nur77 expressionbetween pancreatic cancer, chronic
pancreatitis, benign tumor and control group
In our previous report [12] we have shown that HDAC7 is
significantly expressed in PA tissues samples. Given that only 11
PA tissue specimens and one normal pancreatic biopsy were used,
we performed qPCR analysis of HDACs, SIRTs and Nur77
expression in a total of 46 tissues samples comprising 29 PA.
Moreover, 11 normal pancreatic tissues biopsies were used as the
calibrator to define more accurately the observable mRNA gene
expression levels among the tissues from PA, CP and B. Mean Cp
values (Ct) of HDAC7, Nurr77, SIRT1, SIRT2, were significantly
lower in PA group compared to the CG (p=0.0010; 0.040;
0.0420; 0.0366, respectively) (Figure 2). This result demonstrated
that HDAC7, Nurr77, SIRT1, SIRT2 were significantly over-
expressed in PA samples than in the CG ones.
We then applied the 22DDCt method to analyze the relative gene
expression in tissue samples from PA, B and PC [22]. As shown in
Figure 3A, the expression of HDAC1,2,3,4,7 and Nur77
increased in PA samples at levels significantly higher than those
observed in the case of CP group (p=0.0160; 0.0114; 0.0227;
0.0440; 0.0136; 0.0004, respectively). Moreover, the expression of
HDAC7, was significantly higher in the PA compared to B tissue
samples (p=0.05).
Q RT-PCR analysis showed the expression of various SIRTs
mRNAs in tissues from PA, CP, and B (Figure 3B). Although some
significant variation at the level of SIRTs gene transcription could
be evidenced, the data did not allow to identify a SIRT gene
expression levels variation between PA, CP and B samples.
We further compared the levels of gene expression in some
specimens where we were able to collect biopsies at the tumor
periphery. As shown in Figure 4A, PA samples showed statistically
higher mean mRNA transcription levels for HDAC7 and
HDAC2when compared to their counterpart biopsies taken at
the tumor periphery (p=0.0346, 0.0053, respectively). Although
some degree of variation in SIRTs gene expression levels could be
evidenced between tissue samples, no such remarkable difference
as those observed for HDAC7 and HDAC2 could be seen. These
data support the notion that among the HDACs and SIRTs gene
examined, HDAC7 and HDAC2 are two genes with the highest
potential to be markers of PA.
Patterns and expression levels of HDAC7 and Nur77
When using HDAC7 mAb, the staining was negative or slightly
positive in control cases (NP), whereas strong positive immune
reactivity was found in all PA (Figure 5A). To analyze more
accurately the level of immunostaining in tissues samples, six
stained areas for each immunofluorescence image were quantified
by measuring the MSF intensity of stained areas. All PA exhibited
statistically higher MSF values than control specimens. The
average of the MSF intensity found with mAb to HDAC7 was
significantly increased in PA (mean = 173.7864.46) compared to
the control samples (mean = 54.31613.26) (Figure 5B)
(P=0.0004). Analysis of six stained areas for each immunofluo-
rescence image by measuring the MSF intensity showed that the
average of the MSF values found with mAb to Nur77 was
significantly increased in PA (mean = 146.5068.07) compared to
the control samples (mean =110.0064.41) (Figure 6)
(P=0.0225).
Impact of HDAC7, HDAC2 and Nurr77 expression in
outcome of patient with pancreatic adenocarcinoma
We then examined the possible relationship of gene transcrip-
tion levels (HDAC7,HDAC2 and Nurr77) and the outcome of the
disease. As shown in Figures 7, 8, 9 and 10, no statistically
significant difference could be seen between groups in terms of
overall and disease free survival when considering individuals
expressing more of less than 4 times the baseline gene transcription
level. However, when we analyzed the number of death and
recurrences at the end of follow up, number of death and
recurrences were significantly greater in patient with overexpres-
sion HDAC7 (4 times the baseline gene transcription level)
(Figure 8).
Development of stable human pancreatic cell lines
under-expressing or overexpressing HDAC7
To assess the possible involvement of HDAC7 in cell
proliferation capacity, we generated recombinant human Panc-1
tumoral cell clones using a set of four commercially available
shRNA constructs and a corresponding control plasmid. More-
over, the pCDNA3-HDAC7-Flag plasmid was used to achieve
overexpression of the HDAC7 protein. Transfections were also
performed using a pCDNA3 empty vector as control. Transcrip-
tion of HDAC encoding gene was analyzed by Q RT-PCR. As
shown in Figure 11A, the use of shRNA knockdown approach
resulted in a significant reduction of HDAC7 mRNA production
in 4 obtained cell clones (SH1 Cl17, SH1 Cl24, SH2 Cl6 and SH2
Cl16) compared to Panc-1 shRNA control cell clone (SH CTL-
Cl1), whereas overexpression of HDAC7 gene induced higher
levels of HDAC7 mRNA synthesis in 2 cell clones (pFlag Cl1 and
pFlag Cl3). Complementary experiments using Western blotting
and anti-HDAC7 specific antibodies reacted with total extracts
from different tumor cell populations were performed to examine
whether the alteration of HDAC7 gene expression was associated
with a modification of HDAC7 protein synthesis. Estimation of
HDAC7expression indicated that the recombinant cell clones,
contained approximately 20 to 80% less HDAC7 protein than SH
CTL-Cl1 control cell clone. Moreover, the estimated ratio of
HDAC7 synthesis in Panc-1 tumor cells transformed with the
control vector (pCDNA3) versus those that overexpress HDAC7
was approximately 1 to 300% (Figure 11B). ß-actin protein was
used as internal control.
Growth rates of transfected Panc-1cell clones
As a first step, we determined the growth rates of the cell clones.
The proliferation of Panc-1 parental cells, shRNA, shControl,
HDAC7-FLAG and pCDNA3 transformed tumor cell clones
measured over 96 h of culture is shown in Figure 11C. Interest-
Figure 3. (A) HDACs and Nurr77 genes expression in pancreatic tumor tissues. (B)SIRT genes expression in pancreatic tumor tissues. Tissue
samples from Pancreatic Adenocarcinoma (PA), Benin Tumor (B) and Chronic Pancreatitis (CP). Red line: median of relative RNA transcript levels.
doi:10.1371/journal.pone.0108520.g003
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ingly, the rate of growth was significantly reduced in the case of 3
out of four clone cells carrying shRNA construct targeting
HDAC7 encoding gene when compared to the parental Panc-1
tumor cells (p = 0.0015) at 48 h, and at 96 h of culture still two out
of four clones had significant reduction of cell growth (p = 0.0021).
Moreover, overexpression of HDAC7 did not significantly modify
the growth capacity of parental cells over the time period of
culture (p = 0.3161) suggesting therefore that additional copies of
HDAC7 encoding gene are not necessary to reach optimal growth
for the parental tumor Panc-1 cells.
Discussion
To improve modern cancer therapy, there is an ongoing interest
to identify signaling pathways and genes that might play a key role
in carcinogenesis and the development of resistance to anti-tumor
drugs. Since HDAC interacts with various molecular mechanisms
implicated in gene expression, they have captured the attention of
a large number of researchers. As a family of transcriptional co-
repressors they have emerged as important regulators of cell
differentiation, cell cycle progression and apoptosis [23]. The
dysfunction of transcriptional repression mediated by HDACs
may lead to carcinogenesis. Indeed, alteration of HDACs/SIRTs
expression levels (overexpression and/or downregulation) has been
observed in various types of cancer [24].
Eighteen mammalian HDACs have been characterized and
grouped into four distinct classes: Class I includes HDACs 1, 2, 3
and 8; and Class II, further subdivided in IIa (HDACs 4, 5, 7 and
9) and IIb (HDAC6 and HDAC10). HDAC 11 shares conserved
residues with Class I and II enzymes in their catalytic site and is
allocated to Class IV [24]. Based on their primary structure, the
SIR2 family [Hst proteins (Homologous of Sir two)] or sirtuins are
currently grouped into five different classes [25]: Class I (Human
SIRT1, 2, 3); Class II (SIRT4); Class III (SIRT5) and Class IV
(SIRT6, 7). SIR-T8, which was characterized for the first time in
thyroid carcinoma cell lines and tissue samples [7], was included in
a Class IV.
The prognosis for patients with pancreatic adenocarcinoma is
extremely poor with 5-year survival of less than 5% [26].
Therefore, a number of studies have been devoted to the analysis
of the genetic alterations with the hope to identify putative
biomarkers and/or therapeutic targets [27]. Using molecular
approaches, a large set of genes has been shown to be
overexpressed in pancreatic cancer [12,28,29]. Moreover, bio-
computational tools allowed to demonstrate that among the most
differentially expressed genes in pancreatic cancer were Mesothe-
lin, Muc4, Muc5A/C, Kallikrein 10, Transglutaminase 2, Fascin,
TMPRSS3 and Stratifin [30].
Moreover, alterations in several key genes including those
playing a role in the control of cell cycle (K-ras, p53, p16INK4a,
Figure 4. HDACs and Nurr77 gene expression (A) and SIRTs gene expression (B). Pancreatic adenocarcinoma tumors (PA), remote biopsies
tissues (RB).
doi:10.1371/journal.pone.0108520.g004
Figure 5. Representative results of immunofluorescence stain-
ing with HDAC7 mAb (A). A slight staining is found in NP. In PA, a
strong staining is found in the cytoplasm and in association with the
cell plasma membrane. Original magnification 250x. Quantitative
determination of mean specific fluorescence (MSF) (B). Six areas in
each case were measured. Medians of the MSF intensities obtained with
PA and NP tissues are represented by the horizontal lines and the
interquartile range is represented by boxes. (* P,0.0004).
doi:10.1371/journal.pone.0108520.g005
Figure 6. Representative results of immunofluorescence stain-
ing with Nur77 Ab (A). A moderate staining is found in the
cytoplasm of NP. PA cells are strongly stained in the cytoplasm and a
moderate staining was observed on the cell plasma membranes.
Original magnification 250x. Quantitative determination of mean
specific fluorescence (MSF) (B). Six areas in each case were measured.
Medians of the MSF intensities obtained with PA and NP tissues are
represented by the horizontal lines and the interquartile range is
represented by boxes. (* P,0.0225).
doi:10.1371/journal.pone.0108520.g006
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and Smad4) have also been reported [31]. Furthermore, high
nuclear localization of S100A6, a low molecular weight calcium
binding protein that belongs to S100 family of proteins, is
significantly associated with poor survival in pancreatic cancer
patients [32]. Epigenetic modifications such as changes in histone
acetylation or methylation which influence the chromatin acces-
sibility and gene expression have also been involved in altered
critical genes expression in pancreatic cancer [33].
Given that a number of studies have shown that HDACs/
SIRTs are among key factors that control gene expression, we
have explored in a preliminary report their expression levels in a
relatively few cases of pancreatic surgically resected pancreatic
tissues and found that 9 out of 11 PA samples displayed increased
expression of HDAC7 mRNA transcripts [15]. The present study
was conducted using increased number of pancreatic malignant as
well as normal pancreatic tissues in order to explore more
accurately the HDACs/SIRTs gene expression. The data revealed
that most of the PA tumors analyzed (25/29, 86%) showed
increased expression of HDAC7 encoding gene when compared to
CP and B tumor samples, in agreement with our previous
observations. Moreover, upregulation of HDAC2, an observation
already reported by independent investigators [9,10] has also been
evidenced in our study population of PA.
In the present study, by using a new approach we provide
evidence that several genes namely HDAC7, HDAC2 and Nur77
are overexpressed in significantly high percentage of pancreatic
adenocarcinoma tumors compared to benign tumors and chronic
pancreatitis. The most prominent gene overexpression levels been
observed for HDAC7 encoding gene, in agreement with our
previous preliminary observations. Furthermore, qPCR-based
approach revealed high Nur77 transcript levels associated with
most of the PA tumors, an observation not anticipated, as this link,
to our knowledge, has not been reported for PA tumors.
Furthermore the quantitative method of HDAC7 and Nurr77
immunostaining clearly demonstrate that increased expression of
both genes is associated with adenocarcinomas of the pancreas.
The possible relationship between HDAC7, Nurr77, HDAC2 and
the outcome of the disease was examined. Number of recurrences
were significantly greater in patients with an overexpression of
HDAC7. Recent study demonstrated that HDAC7 silencing by
siRNA was unable to decrease cell growth in BxPC-3 cell lines
[34]. This conflicting result could be explained by the different
characteristics of the cell lines. For example, k-ras was mutated in
Panc-1 and not in BxPC-3 [34]. Moreover, HDAC7 silencing in
our study was obtained by shRNA.
Given the previous studies demonstrating the crucial role of
HDAC7 as regulator in the thymocyte negative selection process
through the down-regulating of the Nur77 gene expression, an
orphan nuclear receptor involved in antigen-induced apoptosis of
Figure 7. Overall and disease free survival of 29 patients with
pancreatic adenocarcinoma. Overall (solid line) and disease-free
survival (dashed line).
doi:10.1371/journal.pone.0108520.g007
Figure 8. Impact of HDAC7 expression on the overall survival (A), the disease free survival (B) and recurrences and death in
patients with pancreatic adenocarcinoma (C). N: base line transcription level in CG.
doi:10.1371/journal.pone.0108520.g008
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Figure 9. Impact of HDAC2 expression on the overall survival (A), the disease free survival (B) and recurrences and death in
patients with pancreatic adenocarcinoma (C). N: base line transcription level in CG.
doi:10.1371/journal.pone.0108520.g009
Figure 10. Impact of Nurr77 expression on the recurrences the overall survival (A), the disease free survival (B) and recurrences and
death in patients with pancreatic adenocarcinoma (C). N: base line transcription level in CG.
doi:10.1371/journal.pone.0108520.g010
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thymocytes [35], we though it would be interesting to determine
the pattern of Nur77 gene expression simultaneously with those
encoding HDAC and SIRTs in pancreatic tumor tissues. Although
Nur77 affects cell proliferation and apoptosis through its capacity
to bind to a variety of response elements leading to the regulation
of their transactivation activities, the intrinsic function of Nur77 is
not yet fully understood. The role of Nur77 as a positive regulator
for apoptosis has been previously reported [36]. The authors
found that in lung cancer cells, Nur77 overexpression is associated
with retinoic acid (RA) resistance, and may contribute to cell
proliferation and neoplastic transformation by blocking the
inhibitory effect of RA on cell growth. Consistent with observa-
tions in this study, Yin et al. [37] also reported that Nur77 caused
a delayed apoptotic process in lung cancer cells. In gastric cancer
cells, translocation of Nur77 from the nucleus to the mitochondria
and the subsequent Cyt c release from the mitochondria to the
cytosol are required for tetradecanoylphorbol-1,3-acetate (TPA) to
induce apoptosis. All-trans retinoic acid (ATRA) does not induce
apoptosis in BGC-823 cells (gastric cancer cell line) in accordance
with its failure of inducing translocation of Nur77 [36]. However,
Nur77 still exerts its function of cell growth inhibition in the
nucleus for the cell cycle regulation [36]. Therefore, these studies,
combined with the reports mentioned above, demonstrate the
divergent functions of Nur77 in the regulation of cell proliferation
Figure 11. Expression of HDAC7 in transfected Panc-1 cell clones in relation to their growth capacity. Panc-1 cells were transfected with
either Sure Silencing shRNA Plasmid for human HDAC7 (left panel) or pCDNA3-HDAC7 plasmid (right panel). Cell clones of each (SH1 CL17/SH1 CL24
and pFlag1/pFlag3, respectively) as well as control vectors (SH CTL and pCDNA3) were analyzed. Normalized relative expression of HDAC7/28S was
assessed by Q RT-PCR (A), Relative expression was calculated using 28S as control gene and normalized to Panc-1 cells. HDAC7 synthesis was
evaluated by Western blot (B). Proliferation of transfected Panc-1 cell clones was evaluated by monitoring their mitochondrial respiratory chain
activity using MTT assay (C). Data are means 6 SD of three independent experiments. Percent proliferation was calculated as follows: at 48 h : OD at
48 h - OD at 24h /OD at 48 h; at 72h : OD at 72 h- OD at 48h / OD at 72 h; at 96h OD at 96h-OD at 72h / OD at 96 h. OD, optic densitometry.
doi:10.1371/journal.pone.0108520.g011
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and apoptosis. The biological significance of Nur77 gene
overexpression and its relation to HDAC7 in PA await further
investigations. It is likely that both genes could participate in the
angionesis process by controlling transcription factors involved in
vascular gene expression. Indeed, it has been reported that
HDAC7 is key modulator of endothelial cell migration and
angiogenesis and regulate PDGF-Bp/PDGF-beta gene expression
[38]. It is difficult to determine at this stage whether upregulation
of HDAC7/HDAC2/Nur77 in pancreatic adenocarcinomas is a
cause or a consequence of malignant progression. It is likely that
the HDAC7 in pancreatic cancer could use the VEGF-PKD-
HDAC7 axis in the settings of vascular disorders and could explain
the potential metastatic of pancreatic cancer.
With more investigations, the involvement of HDAC7/
HDAC2/Nur77 in the pathogenesis of pancreatic tumors can be
clarified. It might lead to the appropriate utilization of the
HDAC7/HDAC2/Nur77 as adjunctive markers for malignancy
in pancreatic cancer, and towards the development of new
approaches in the design of anti-pancreatic cancer therapy.
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